

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

R-ONE[®] VASCULAR INTERVENTIONAL SURGICAL ROBOT COMPLETED ENROLLMENT FOR REGISTRATIONAL CLINICAL TRIAL

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The board of directors (the “**Board**”) of the Company is hereby pleased to announce that the R-ONE[®] Vascular Interventional Surgical Robot (the “**R-ONE[®]**”) introduced by the Cathbot (Shanghai) Robot Co., Ltd., a joint venture company in China jointly established by the Company and Robocath S.A.S in France, has completed enrollment for registrational clinical trial, becoming the first cardiovascular interventional surgical robot system in China that has completed multi-center registrational clinical trials. The 301 Hospital led the registrational clinical trials, and Shanxi Cardiovascular Hospital, Meizhou People’s Hospital and People’s Hospital of Xinjiang have also participated in the clinical trials. During the clinical trials, R-ONE[®] completed surgeries on complex medical conditions such as the two crimal blood vessels long diffuse lesion, a highly tortuous vessel with poor co-axiality, long diffuse lesion, calcified lesions, ectopic opening as well as subtotal occlusion, and had records of completing three surgeries in a row, which has fully demonstrated its stability and reliability.

ABOUT R-ONE[®]

R-ONE[®] is a vascular intervention control system based on master-slave control technologies. Leveraging on various core patents, it is designed to assist physicians to complete PCI surgeries in a more precise, efficient and reliable way. The system also features a short learning curve and a lower risk of surgical complications. In addition, by using R-ONE[®], surgeons can be seated behind the radiation-proof control panel to operate remotely, which can effectively reduce the exposure time under radiation while achieving precise surgical operations.

IMPLICATIONS TO THE COMPANY

The completion of enrollment for registrational clinical trial of R-ONE[®] is another significant breakthrough for the Company in the field of pan-vascular intervention. It marks the new phase of robot-assisted vascular interventional surgery in China, and lays an important foundation for more precise and intelligent and less invasive vascular interventional surgery. In the future, the Company will continue to strengthen the close cooperation with clinical experts and will make use of the advantages of the Group's operation together with the help of more academic experts nationwide to trickle down high-quality medical resources and provide precise, intelligent and inclusive robotic surgery solutions to more patients.

The Company cannot guarantee that R-ONE[®] will be marketed successfully in China. Shareholders of the Company and potential investors are advised to exercise caution when dealing in shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Mr. Sun Hongbin
Chairman

Shanghai, China, 26 May 2022

As at the date of this announcement, the executive Director is Dr. He Chao, the non-executive Directors are Mr. Sun Hongbin, Mr. Sun Xin and Mr. Chen Chen, and the independent non-executive Directors are Ms. Lee Kit Ying, Dr. Li Minghua and Mr. Yao Haisong.